Skip to Main Content

Paper Details

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Clin Cancer Res
40
2020
ER, HER2, HER2-Positive Breast Cancer, HER2-positive breast cancer, HER2-positive breast tumors, Lapatinib, Letrozole, PATIENTS, Patients, TBCRC023, Trastuzumab, Women, acneiform rash, breast cancer, diarrhea, estrogen, estrogen receptor, lapatinib, patients, trastuzumab, tumors, women
Author NameAffiliation
Mothaffar F RimawiBaylor College of Medicine
Mothaffar F RimawiBaylor College of Medicine
Mothaffar F RimawiDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Antonio C WolffJohns Hopkins University
Rita NandaUniversity of Chicago
Anna Maria StornioloIndiana University School of Medicine
Ian E KropDana Farber Cancer Institute
Matthew P GoetzMayo Clinic
Julie NangiaDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Anna C PavlickBaylor College of Medicine
Anna C PavlickDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Susan G HilsenbeckBaylor College of Medicine
Susan G HilsenbeckDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Susan G HilsenbeckBaylor College of Medicine
  • 1 - 14

Datasets

Release 1.2